Diagnostics with biomarker patterns in extracellular vesicles (KI-VesD-2)
Liquid biopsy enables the minimally invasive early detection of tumors and their progression. KI-VesD-2 assesses the innate immune response to tumor development by extracting extracellular vesicles (EV) from blood and analyzing them using artificial intelligence.
EV are secreted by all cells of the body, including immune, organ and tumor cells, and contain a different composition of biomarkers (proteins, microRNA, mRNA, enzymes) depending on the state of their parent cells. The extraction of EV from body fluids and their analysis therefore allows conclusions to be drawn about the state of the parent cells and thus about the state of the immune system and any tumors present.
So far, only few approaches utilizing EV biomarkers have found their way into medical diagnostics. One reason for this is the lack of suitable purification methods. Methods used in EV research are not suitable for clinical diagnostics. Building on the predecessor project KI-VesD-1, cartridges and devices are therefore being developed to automatically purify EV both microfluidically and chromatographically and make them available for diagnostic applications. The EV markers are analyzed using artificial intelligence (AI) methods. The AI is to be trained with patient samples for the (early) detection of prostate carcinoma and the therapy/relapse monitoring of melanoma.
- Project
- Diagnostik mit Biomarkermustern aus extrazellulären Vesikeln des Plasmas (pEV) mit Methoden der künstlichen Intelligenz (KI)
- Sponsor
-
BMBF
- Promoter
-
VDI/VDE/IT
- Funding Number
- 16LW0339
- Duration
- 01.04.2023 to 31.03.2026
- Cooperation Partner
- Universitätsklinikum Erlangen (Hautklinik, Urologische und Kinderurologische Klinik, Medizinische Klinik 5)
- Maturity Level
-
Functional model